Anika Pekala - Publications

Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study.

Journal: The oncologist

Published: May 07, 2026

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study.

Journal: Journal of neuro-oncology

Published: December 03, 2025

The polish validation of a disease-specific patient-reported outcome measure of systemic lupus erythematosus.

Journal: Lupus

Published: November 26, 2025

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe.

Journal: The oncologist

Published: November 23, 2025

Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.

Journal: Oncology research

Published: November 19, 2025

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 17, 2025

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study.

Journal: Breast (Edinburgh, Scotland)

Published: October 28, 2025

Risk Factors and Clinicopathological Features for Developing a Subsequent Primary Cutaneous Squamous and Basal Cell Carcinomas.

Journal: Cancers

Published: April 26, 2022